Key Takeaways:
- Gilead Sciences faces a slight EPS guidance revision, affecting investor sentiment.
- Analysts project a potential upside for GILD stock in the next 12 months.
- Current GF Value suggests the stock might be overvalued, according to GuruFocus metrics.
Gilead Sciences (GILD, Financial) saw its shares decline approximately 3% in after-hours trading after it adjusted its 2025 diluted earnings per share (EPS) guidance. The revised range is $5.65 to $6.05, down from the previous projection of $5.95 to $6.35. Despite this EPS revision, the company's revenue forecast remains unchanged at $28.2 billion to $28.6 billion, which falls short of Wall Street's consensus of $28.73 billion.
Wall Street Analysts' Predictions
According to the insights from 24 Wall Street analysts, the average price target for Gilead Sciences Inc (GILD, Financial) over the next year is positioned at $112.27. This estimate includes a high target of $140.00 and a low of $82.00. The average forecast suggests a potential upside of 5.77% from the current stock price of $106.15. For more comprehensive estimates, visit the Gilead Sciences Inc (GILD) Forecast page.
Reflecting on brokerage recommendations, Gilead Sciences Inc (GILD, Financial) garners an average rating of 2.1 from 30 firms, classifying it under the "Outperform" category. This rating system ranges from 1, indicating a Strong Buy, to 5, representing a Sell.
Gilead's GF Value Insights
GuruFocus provides an estimated GF Value for Gilead Sciences Inc (GILD, Financial), which stands at $80.51 for the upcoming year. This valuation suggests a potential downside of 24.15% from the current trading price of $106.15. The GF Value is GuruFocus' assessment of the stock's fair trading value, derived from historical valuation multiples, past business growth metrics, and projected future business performance. Investors can access additional data on the Gilead Sciences Inc (GILD) Summary page.
